ArticleRadiologie (Heidelberg, Germany)2026
[Combination of radiotherapy and medicinal anticancer therapy with curative intent].
Article in Radiologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Curative treatment in oncology requires complete local and systemic tumor control. A special option here is the combination of radiotherapy with systemic therapy. Combining the local effect of radiotherapy with the systemic effect of drug therapy creates synergies that can further increase the resulting control rates. In addition, radiotherapy and systemic therapy primarily reinforce each other in their local effects but also have systemic effects, especially in combination with immunotherapy. The combination of radiotherapy and chemotherapy has long been established and is increasingly being supplemented by immunotherapy or treatment with tyrosine kinase inhibitors. The combination of radiotherapy with antihormonal treatment has also become more important. This leads to higher success rates in both remission and healing.
Indexed as
Identifiers
42848197What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.